Clinical Trial Update: Systemic Avastin Therapy in Age-Related Macular Degeneration [Phase 2, Phase 3]

View source ↗

Summary

Updates from Phase 2 and Phase 3 trials of systemic bevacizumab (Avastin) for age-related macular degeneration, with the study status showing completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Avastin (bevacizumab)

Snippet

Sponsor: The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery | Conditions: Macular Degeneration | Phase 2, Phase 3 | Status: COMPLETED